5.05

1.41% 0.07

After Hours: 5.05

Vanda Pharmaceuticals Inc (VNDA)

Overview News Price History Option Chain Financials Discussions Forecast

Vanda Pharmaceuticals Inc stock is traded at $5.05, with a volume of 722.60K. It is up +1.41% in the last 24 hours and down -7.17% over the past month. Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include ASO Molecules, VQW-765, Tradipitant, and VTR-297. The maximum of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.

Previous Close:

$4.98

Open:

$5.01

24h Volume:

722.60K

Relative Volume:

0.82

Market Cap:

$305.34M

Revenue:

$217.78M

Net Income/Loss:

$-239.55M

P/E Ratio:

-1.2472

EPS:

-4.0492

Net Cash Flow:

$-127.30M

1W Performance:

-1.56%

1M Performance:

-7.17%

6M Performance:

-30.34%

1Y Performance:

+4.55%

1-Day Range:

$4.93

$5.07

1-Week Range:

$4.93

$5.33

52-Week Range:

$4.27

$9.94

Vanda Pharmaceuticals Inc Stock (VNDA) Company Profile

Name

Vanda Pharmaceuticals Inc

Sector

Healthcare (1067)

Industry

Biotechnology (595)

Phone

202-734-3400

Address

2200 PENNSYLVANIA AVE NW, WASHINGTON

Employee

533

Twitter

Next Earnings Date

2026-11-04

Latest SEC Filings

VNDA's Discussions on Twitter

Compare VNDA vs VRTX, REGN, MRNA, ARGX, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
VNDA Vanda Pharmaceuticals Inc	5.05	305.34M	217.78M	-239.55M	-127.30M	-4.0492
VRTX Vertex Pharmaceuticals Inc	526.19	133.37B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	788.04	81.13B	14.92B	4.42B	3.79B	41.04
MRNA Moderna Inc	198.88	79.40B	2.23B	-3.19B	-1.60B	-8.1462
ARGX Argen X Se Adr	959.49	60.03B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	204.97	43.93B	742.00K	-1.37B	-1.07B	-7.0731

Vanda Pharmaceuticals Inc Stock (VNDA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-05-26	Initiated	Truist	Buy
Nov-05-25	Initiated	B. Riley Securities	Buy
Oct-31-24	Initiated	H.C. Wainwright	Buy
Jul-11-24	Initiated	Cantor Fitzgerald	Overweight
Feb-25-22	Downgrade	Jefferies	Buy → Hold
May-12-21	Initiated	BofA Securities	Buy
Jan-14-21	Downgrade	Citigroup	Buy → Neutral
Oct-29-20	Upgrade	Citigroup	Neutral → Buy
Jun-09-20	Downgrade	Citigroup	Buy → Neutral
Mar-16-20	Downgrade	Oppenheimer	Perform → Underperform
Mar-12-20	Upgrade	Citigroup	Neutral → Buy
Nov-07-19	Downgrade	Citigroup	Buy → Neutral
Aug-01-19	Upgrade	Citigroup	Neutral → Buy
Jul-25-19	Downgrade	Stifel	Buy → Hold
Dec-11-18	Downgrade	Oppenheimer	Outperform → Perform
Dec-04-18	Upgrade	Cantor Fitzgerald	Neutral → Overweight
Dec-04-18	Reiterated	Jefferies	Buy
Nov-08-18	Resumed	Jefferies	Buy
Sep-21-18	Resumed	Oppenheimer	Outperform
May-23-18	Initiated	Citigroup	Buy
Jan-19-18	Initiated	Seaport Global Securities	Buy
Sep-14-17	Reiterated	Piper Jaffray	Overweight
Jun-27-17	Resumed	Piper Jaffray	Overweight
May-26-17	Initiated	H.C. Wainwright	Buy
Apr-12-17	Initiated	Oppenheimer	Outperform
Nov-09-16	Initiated	Aegis Capital	Buy
Oct-06-16	Resumed	Jefferies	Buy

View All

Vanda Pharmaceuticals Inc Stock (VNDA) Latest News

Sep 26, 2026

VNDA Stock Gains After-Hours As FDA Grants Rare Pediatric Disease Designation For Experimental Therapy - Stocktwits

Sep 26, 2026

Vanda Stock Draws Heavy Buzz Ahead Of FDA Verdict On Bysanti For Bipolar, Schizophrenia - Stocktwits

Sep 26, 2026

Teva, Apotex Don't Infringe Sleep Drug Patents, Judge Finds - Law360

Sep 26, 2026

Sep 25, 2026

Teva, Apotex Beat Vanda Patent Claims Over Hetlioz Sleep Drug - Bloomberg Law News

Sep 25, 2026

Sep 24, 2026

Vanda Pharma Stock Rises Pre-Market After FDA Accepts Imsidolimab Filing For Rare Skin Disorder - Stocktwits

Sep 24, 2026

Sep 23, 2026

VNDA Initiates Coverage On Oppenheimer -- Rating Outperform with $10.00 Price Target - GuruFocus

Sep 23, 2026

Oppenheimer initiates Vanda Pharmaceuticals stock with outperform rating By Investing.com - Investing.com South Africa

Sep 23, 2026

Oppenheimer initiates Vanda Pharmaceuticals stock with outperform rating - Investing.com

Sep 23, 2026

Sep 18, 2026

Vanda Pharmaceuticals stock slips as 2025 loss widens - AD HOC NEWS

Sep 18, 2026

Sep 15, 2026

Vanda Pharmaceuticals at H.C. Wainwright conference: pipeline broadens By Investing.com - Investing.com Canada

Sep 15, 2026

VNDA: BYSANTI and NEREUS launches, plus pivotal readouts, set up major growth opportunities ahead - TradingView

Sep 15, 2026

Sep 12, 2026

Vanda Now Looks To Public Hearing For Hetlioz In Jet Lag Disorder After Multiple FDA Rejections - Stocktwits

Sep 12, 2026

VNDA Stock Soars 40% Overnight After Bysanti Approval: What’s The Next Catalyst And How Much Upside Remains? - Stocktwits

Sep 12, 2026

Why Did Vanda Pharmaceuticals Stock Slide 7% Pre-Market Today? - Stocktwits

Sep 12, 2026

Sep 11, 2026

VNDA: BYSANTI and NEREUS launches, plus pipeline catalysts, set the stage for major revenue growth - TradingView

Sep 11, 2026

Vanda Pharmaceuticals at Cantor conference: psychiatry push takes center stage - Investing.com Canada

Sep 11, 2026

VNDA: BYSANTI and NEREUS launches, plus key phase III trials, set the stage for major revenue growth - TradingView

Sep 11, 2026

Sep 06, 2026

VNDA Stock Rises After Hours On Commercial Launch Of Motion Sickness Drug - Stocktwits

Sep 06, 2026

Sep 05, 2026

Vanda Pharmaceuticals Stock Price Forecast. Should You Buy VNDA? - StockInvest.us

Sep 05, 2026

Sep 04, 2026